Irving H FoxIrving and Gloria Fox have been married for more than 56 years and have 3 daughters and 3 sons-in-law and 7 grandchildren aged 8 to 20. Irving was born in Montreal Canada and attended McGill Medical School and graduated in 1967. His Postdoctoral traiing was at Duke University which was completed in 1972. His career was in academic medicine and industry. His academic medicine career extended from 1972 to 2008. He held full-time faculty positions at the University of Toronto and the University of Michigan and a part-time clinical appointment at Harvard Medical School starting in 1991. At Michigan, he was appointed to full professorships in internal medicine and biological chemistry and major administrative responsibilities including rheumatology division chief and director of the clinical research center. At HMS he was appointed Clinical Professor of Medicine, part-time, with appointments at Massachusetts General Hospital and then Beth Israel Deaconess Medical Center (BIDMC) for 17 years while working in Biotech and Pharma. He is currently trustee emeritus at BIDMC Board of trustees. His industry R&D work was at Biogen and then Millennium/Takeda. As VP at Biogen, he led the clinical team that achieved the original marketing authorization in the US and EU for Avonex, one of the first biologic treatments for multiple sclerosis. At Millennium/Takeda he was a leader of the clinical team in 2014 that achieved marketing authorization and patient access for Entyvio for the treatment of Crohn's Disease and Ulcerative Colitis in the US and EU. His prior R&D work and product approvals have significantly improved thousands of lives. His mentoring in both academic medicine and industry has impacted the careers of numerous people who have worked with him. Read More Read Less